Vivesto is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Vivesto’s proprietary drug delivery platform ™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Vivesto’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: VIVE). To find out more about Vivesto please visit https://www.vivesto.com/en/.
Company Details
- Employees
- 26
- Founded
- -
- Address
- Vallongatan 1 Se, Uppsala,752 28,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- oasmia.com
- Keywords
- Willington.
- HQ
- Uppsala
Vivesto Questions
Vivesto's website is oasmia.com
Vivesto's LinkedIn profile is https://se.linkedin.com/company/vivesto
Vivesto has
26 employees.
View email and phone details for 26
employees at Vivesto.
Vivesto's industry is
Pharmaceutical Manufacturing
Vivesto's top competitors are
Elevar Therapeutics,
Orexo Ab Publ.,
Lidds,
Oncopeptides Ab (Publ),
Dicot Pharma Ab,
Diamyd Medical,
Inceptua Group,
Wntresearch Ab,
Tanner Pharma Group,
Bionical Emas.
Vivesto's categories are Pharmaceutical Manufacturing
Vivesto's founding year is 1999
